This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol-Myers (BMY) Wins EC Approval for MS Drug Zeposia
by Zacks Equity Research
Bristol-Myers (BMY) gets EC nod for Zeposia for the treatment of adult patients with relapsing remitting multiple sclerosis.
S&P Reclaims 3,000 Mark: Go Long With These ETFs
by Sweta Killa
Wall Street is rallying this quarter with the S&P 500 reclaiming its 3,000 level.
Stock Market News for May 27, 2020
by Zacks Equity Research
The three major indexes closed in the green on Tuesday, as investors remained hopeful about coronavirus vaccine and that economies around the globe were recovering from the pandemic-driven lockdown over the past few months.
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Biotech ETF (BBC) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Merck Inks 3 Deals for Coronavirus Anti-infective & Vaccines
by Zacks Equity Research
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
Dow Touches 25,000 in More Than 2 Months: 4 Blue-Chip Picks
by Nalak Das
The blue-chip index's northbound journey began on Mar 24 and is continuing barring occasional fluctuations.
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
S&P Set to Open Above 3000
by Jeremy Mullin
Bulls start the week trying to break the 200-day moving average.
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug
by Zacks Equity Research
Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.
Can Teva (TEVA) Return to Growth in This Year or Next?
by Zacks Equity Research
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
by Kinjel Shah
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
by Zacks Equity Research
FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.
Roche's Tecentriq Gets FDA Approval for Metastatic NSCLC
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for the label expansion of Tecentriq into metastatic NSCLC as a first-line monotherapy.
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer
by Zacks Equity Research
Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
BMY or MRK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. MRK: Which Stock Is the Better Value Option?
Bristol Myers' Opdivo+Yervoy Gets FDA Nod in First-Line NSCLC
by Zacks Equity Research
Bristol-Myers (BMY) Opdivo in combination with Yervoy gets FDA nod for the first-line treatment of NSCLC patients.
Merck's (MRK) Keytruda Successful in Several Cancer Studies
by Zacks Equity Research
Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.
Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY
by Kinjel Shah
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
Roche Posts Positive Phase II Results on Immunotherapy Combo
by Zacks Equity Research
Roche's (RHHBY) mid-stage study on immunotherapy, tiragolumab, combined with PD-L1 checkpoint inhibitor, Tecentriq, meets co-primary endpoints.
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - May 14, 2020
by Zacks Equity Research
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - May 14, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA
by Zacks Equity Research
Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
by Sweta Jaiswal, FRM
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.